Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02820896 · ClinicalTrials.gov registry record · Phase 1
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02820896 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 74 participants.
The verdict
NCT02820896, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This is a Phase I, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7105705 in two participant populations: healthy participants and participants with mild-to-moderate Alzheimer's disease. This study is a single dose, dose-escalation, and multiple dose study comprising approximately six single dose cohorts in healthy participants administered RO7105705, either intravenously (IV) or subcutaneously (SC), and comprising one or more multiple dose cohorts in healthy participants administered RO7105705 IV every week (QW), a total of 4 doses, and one or more multiple dose cohorts in participants with Alzheimer's disease administered RO7105705 IV QW, a total of 4 doses.
Interventions
- DRUG Placebo
- DRUG RO7105705
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-06-29 |
| Est. Completion | 2017-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02820896
The ClinicalTrials.gov registry entry for NCT02820896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02820896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02820896 about?
NCT02820896 is a clinical study titled "A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease". This is a Phase I, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7105705 in two participant populations: healthy participants and participants with mild-to-moderate Alzheimer's disease. This study is a single ...
What is the current status of trial NCT02820896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2016-06-29. Estimated completion is 2017-06-26.
What interventions are being tested in trial NCT02820896?
The interventions under investigation include: Placebo (DRUG), RO7105705 (DRUG).
Who is sponsoring clinical trial NCT02820896?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.